Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 123

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Mechanisms Underlying Visceral Hypersensitivity in Irritable Bowel Syndrome

Barbara, Giovanni, Cremon, Cesare, De Giorgio, Roberto, Dothel, Giovanni, Zecchi, Lisa, Bellacosa, Lara, Carini, Giovanni, Stanghellini, Vincenzo, Corinaldesi, Roberto·2011·Current Gastroenterology Reports
DOI 10.1007/s11894-011-0195-7
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11894-011-0195-7

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 77

  1. Azpiroz F, Bouin M, Camilleri M, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil. 2007;19(1 Suppl):62–88. · DOI
  2. Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology. 2000;118:842–8. · DOI · Paper page
  3. Seminowicz DA, Labus JS, Bueller JA, et al. Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology. 2010;139:48–57. · DOI · Paper page
  4. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology. 1997;112:1714–43. · DOI
  5. Mayer EA, Bradesi S, Chang L, et al. Functional GI disorders: from animal models to drug development. Gut. 2008;57:384–404. · DOI
  6. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–11. · DOI · Paper page
  7. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006;24:21–37. · DOI
  8. Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005;22:935–42. · DOI
  9. Saito YA, Schoenfeld P, Locke 3rd GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–5.
  10. Chang L, Toner BB, Fukudo S, et al. Gender, age, society, culture, and the patient’s perspective in the functional gastrointestinal disorders. Gastroenterology. 2006;130:1435–46. · DOI · Paper page
  11. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002;16:1171–85. · DOI
  12. Barbara G, De Giorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20 Suppl 2:1–9. · DOI
  13. Vergnolle N. Postinflammatory visceral sensitivity and pain mechanisms. Neurogastroenterol Motil. 2008;20 Suppl 1:73–80. · DOI
  14. • Spiller R, Garsed K: Postinfectious irritable bowel syndrome. Gastroenterology 2009, 136:1979–1988. Extensive review evaluating the role of infectious enteritis in the pathogenesis of IBS (post-infectious IBS). · DOI · Paper page
  15. Greenwood-van Meerveld B. Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity. Neurogastroenterol Motil. 2007;19 Suppl 2:13–8. · DOI
  16. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut. 1973;14:125–32. · DOI · Paper page
  17. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology. 1990;98:1187–92. · DOI · Paper page
  18. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109:40–52. · DOI · Paper page
  19. • Camilleri M, McKinzie S, Busciglio I, et al.: Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008, 6:772–781. This is a large prospective study, assessing the contribution of sensory and motor dysfunction in the pathophysiology of IBS. In contrast with previous publications carried out smaller series, the authors showed that increased sensation to distensions, including hypersensitivity and hyperalgesia was detected in only 20% of patients. · DOI
  20. • Barbara G, Stanghellini V: Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut 2009, 58:1571–1575. This is a critical overview on the potential role of pathophysiologic mechanisms as biomarkers of IBS. · DOI
  21. Trimble KC, Farouk R, Pryde A, et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci. 1995;40:1607–13. · DOI
  22. Zighelboim J, Talley NJ, Phillips SF, et al. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci. 1995;40:819–27. · DOI
  23. Accarino AM, Azpiroz F, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology. 1995;108:636–43. · DOI · Paper page
  24. Cook IJ, Van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology. 1987;93:727–33. · DOI
  25. Chang L, Mayer EA, Johnson T, et al. Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain. 2000;84:297–307. · DOI
  26. Simrén M, Agerforz P, Björnsson ES, Abrahamsson H. Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2007;19:20–9. · DOI
  27. Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut. 2001;48:20–7. · DOI
  28. Simrén M, Abrahamsson H, Björnsson ES. Lipid-induced colonic hypersensitivity in the irritable bowel syndrome: the role of bowel habit, sex, and psychologic factors. Clin Gastroenterol Hepatol. 2007;5:201–8. · DOI
  29. Dickhaus B, Mayer EA, Firooz N, et al. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol. 2003;98:135–43. · DOI
  30. Poitras P, Riberdy Poitras M, Plourde V, et al. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci. 2002;47:914–20. · DOI
  31. Posserud I, Syrous A, Lindström L, et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology. 2007;133:1113–23. · DOI · Paper page
  32. van der Veek PP, Van Rood YR, Masclee AA. Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008;6:321–8. · DOI
  33. Accarino AM, Azpiroz F, Malagelada JR. Attention and distraction: effects on gut perception. Gastroenterology. 1997;113:415–22. · DOI
  34. Elsenbruch S, Rosenberger C, Bingel U, et al. Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology. 2010;139:1310–9. · DOI
  35. Barbara G, Stanghellini V, Cremon C, et al. What is the effect of inflammation on intestinal function? Inflamm Bowel Dis. 2008;14 Suppl 2:S140–4. · DOI
  36. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology. 1996;111:1683–99. · DOI · Paper page
  37. Sturiale S, Barbara G, Qiu B, et al. Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci U S A. 1999;96:11653–8. · DOI
  38. Barbara G, Vallance BA, Collins SM. Persistent enteric neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology. 1997;112:1224–8. · DOI
  39. Barbara G, De Giorgio R, Deng Y, et al. Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology. 2001;120:1729–36. · DOI
  40. Calabrese C, Fabbri A, Bortolotti M, et al. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther. 2003;18:525–32. · DOI
  41. Walker MM, Salehian SS, Murray CE, et al. Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia. Aliment Pharmacol Ther. 2010;31:1229–36. · DOI
  42. Barbara G, De Giorgio R, Stanghellini V, et al. A role for inflammation in irritable bowel syndrome? Gut. 2002;51 Suppl 1:i41–4. · DOI
  43. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163–73. · DOI · Paper page
  44. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology. 1994;107:271–93. · DOI
  45. Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut. 1983;24:190–2. · DOI · Paper page
  46. Simrén M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389–96. · DOI · Paper page
  47. Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007;13:175–81. · DOI
  48. O’Leary C, Wieneke P, Buckley S, et al. Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol. 2002;97:1463–7. · DOI
  49. • Barbara G, Wang B, Stanghellini V, et al.: Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007, 132:26–37. This translational study showed that mediators obtained from colonic mucosa of patients with IBS excite nociceptive visceral sensory pathways in rats, providing the importance of peripheral factors on visceral sensory activation in IBS. · DOI · Paper page
  50. Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137:1425–34. · DOI · Paper page
  51. Hughes PA, Brierley SM, Martin CM, et al. TRPV1-expressing sensory fibres and IBS: links with immune function. Gut. 2009;58:465–6. · DOI
  52. Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil. 2006;18:6–17. · DOI
  53. Gué M, Del Rio-Lacheze C, Eutamene H, et al. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil. 1997;9:271–9. · DOI · Paper page
  54. • Klooker TK, Braak B, Koopman KE, et al.: The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010, 59:1213–1221. This pilot, randomized, double-blind, controlled trial showed that the mast cell stabilizer ketotifen, but not placebo, increased the threshold for discomfort in patients with IBS with visceral hypersensitivity and reduced IBS symptoms. · DOI
  55. Grundy D. 5-HT system in the gut: roles in the regulation of visceral sensitivity and motor functions. Eur Rev Med Pharmacol Sci. 2008;12 Suppl 1:63–7.
  56. Geppetti P, Trevisani M. Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function. Br J Pharmacol. 2004;141:1313–20. · DOI
  57. Jones 3rd RC, Xu L, Gebhart GF. The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci. 2005;25:10981–9. · DOI · Paper page
  58. Chan CL, Facer P, Davis JB, et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet. 2003;361:385–91. · DOI · Paper page
  59. Barbara G, Gargano L, Cremon C, et al. Nerve growth and plasticity in the colonic mucosa of patients with irritable bowel syndrome. Gastroenterology. 2010;138:S-65. · DOI
  60. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today. 2009;14:56–67. · DOI
  61. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev. 1991;43:143–201. · DOI
  62. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 agonist) therapy for pain relief: farewell or revival? Clin J Pain. 2008;24:142–54. · DOI · Paper page
  63. Bortolotti M. Effect of red pepper on symptoms of irritable bowel syndrome (IBS): a preliminary study. Gastroenterology. 2010;138:S-232. · DOI
  64. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397–414. · DOI · Paper page
  65. Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol Motil. 2005;17:637–42. · DOI
  66. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil. 2007;19 Suppl 2:25–31. · DOI
  67. De Giorgio R, Barbara G, Furness JB, Tonini M. Novel therapeutic targets for enteric nervous system disorders. Trends Pharmacol Sci. 2007;28:473–81. · DOI
  68. Hillsley K, Grundy D. Sensitivity to 5-hydroxytryptamine in different afferent subpopulations within mesenteric nerves supplying the rat jejunum. J Physiol. 1998;509(Pt 3):717–27. · DOI
  69. Kreis ME, Jiang W, Kirkup AJ, Grundy D. Cosensitivity of vagal mucosal afferents to histamine and 5-HT in the rat jejunum. Am J Physiol Gastrointest Liver Physiol. 2002;283:G612–7. · DOI
  70. Hicks GA, Coldwell JR, Schindler M, et al. Excitation of rat colonic afferent fibres by 5-HT(3) receptors. J Physiol. 2002;544(Pt 3):861–9. · DOI
  71. Kozlowski CM, Green A, Grundy D, et al. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut. 2000;46:474–80. · DOI
  72. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035–40. · DOI
  73. Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009;104:1831–43. · DOI · Paper page
  74. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004;126:1657–64. · DOI
  75. Camilleri M, Andrews CN, Bharucha AE, et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology. 2007;132:17–25. · DOI
  76. Cremon C, Carini G, De Giorgio R, et al. Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon? Expert Rev Mol Diagn. 2010;10:389–93. · DOI
  77. Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil. 2007;19:545–52. · DOI

Cited by

See all 123

Metadata

Authors
Barbara, G., Cremon, C., De Giorgio, R., Dothel, G., Zecchi, L., Bellacosa, L., Carini, G., Stanghellini, V., & Corinaldesi, R.
Venue
Current Gastroenterology Reports
Publisher
Springer Science and Business Media LLC
Published
2011-05-03
Volume
13
Issue
4
Pages
308-315
ISSN
  • 1522-8037
  • 1534-312X
DOI
10.1007/s11894-011-0195-7
Cited by
123
References
22
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.